What are Asit Parikh’s Phathom (PHAT) share holdings after these transactions?

Following the reported transactions, Parikh holds 52,122 Phathom common shares directly. He also has 120,500 shares reported as indirectly owned through a trust, providing both direct and trust-based exposure to the company’s equity.

Phathom (NASDAQ: PHAT) director gains shares via options and RSUs

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Phathom Pharmaceuticals director Asit Parikh reported equity compensation and an option exercise that increased his share holdings. He exercised options to acquire 17,500 shares of common stock at $4.95 per share, and the corresponding right to buy 17,500 shares was surrendered back to the company.

Parikh also received a grant of 24,122 Restricted Stock Units under the Non-Employee Director Compensation Program. These RSUs vest in full on the earlier of the first anniversary of the May 19, 2026 grant date or the next annual stockholder meeting, subject to continued board service. After these transactions, he holds 52,122 shares directly and 120,500 shares indirectly through a trust.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Parikh Asit

Role null

Type	Security	Shares	Price	Value
Disposition	Common Stock (Right to Buy)	17,500	$0.00	--
Exercise	Common Stock	17,500	$4.95	$87K
Grant/Award	Common Stock	24,122	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock (Right to Buy) — 0 shares (Direct, null); Common Stock — 52,122 shares (Direct, null); Common Stock — 120,500 shares (Indirect, by Trust)

Footnotes (1)

[object Object]

Key Figures

Option exercise shares: 17,500 shares Option exercise price: $4.95/share RSU grant size: 24,122 units +3 more

6 metrics

Option exercise shares 17,500 shares Common Stock acquired via option exercise at $4.95 on May 20, 2026

Option exercise price $4.95/share Exercise or conversion price for 17,500-share option

RSU grant size 24,122 units Restricted Stock Units granted May 19, 2026 to non-employee director

Direct holdings after transactions 52,122 shares Common Stock directly owned by Asit Parikh after reported transactions

Indirect holdings via trust 120,500 shares Common Stock indirectly owned by trust as of May 19, 2026

Option expiration date June 2, 2035 Original expiration date of exercised 17,500-share option

Key Terms

Restricted Stock Units ("RSUs"), Non-Employee Director Compensation Program, disposition to issuer, contingent right to receive one share, +1 more

5 terms

Restricted Stock Units ("RSUs") financial

"The Restricted Stock Units ("RSUs") were granted on May 19, 2026"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Non-Employee Director Compensation Program financial

"pursuant to the Issuer's Non-Employee Director Compensation Program"

disposition to issuer financial

"transaction_code_description":"Disposition to issuer""

indirect ownership by Trust financial

"total_shares_following_transaction":"120500.0000" ... "nature_of_ownership":"by Trust""

Form 4 Insider Transactions: What Each Field Means →

05/21/2026 - 05:16 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parikh Asit

(Last)

(First)

(Middle)

C/O PHATHOM PHARMACEUTICALS, INC.

100 CAMPUS DRIVE, SUITE 102

(Street)

FLORHAM PARK

NEW JERSEY

07932

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Phathom Pharmaceuticals, Inc. [ PHAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/19/2026		A		24,122⁽¹⁾	A	$0	34,622	D
Common Stock	05/20/2026		M		17,500	A	$4.95	52,122	D
Common Stock								120,500	I	by Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock (Right to Buy)	$4.95	05/20/2026		D			17,500	05/19/2026	06/02/2035	Common Stock	17,500	$0	0	D

Explanation of Responses:

1. The Restricted Stock Units ("RSUs") were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

	/s/ Anne Marie Cook, Attorney-in-Fact for Asit Parikh	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did PHAT director Asit Parikh report?

Asit Parikh reported exercising options for 17,500 Phathom shares at $4.95 and receiving 24,122 Restricted Stock Units as a board compensation grant. He also reported updated direct and indirect common stock holdings after these transactions.

How many Phathom (PHAT) shares did Asit Parikh acquire through option exercise?

He acquired 17,500 shares of Phathom common stock by exercising options at $4.95 per share. This derivative exercise converted a right to buy shares into actual stock while canceling the underlying option position for the same share amount.

What RSU grant did Asit Parikh receive from Phathom Pharmaceuticals (PHAT)?

Parikh received 24,122 Restricted Stock Units under Phathom’s Non-Employee Director Compensation Program. Each RSU represents one common share, with 100% vesting on the earlier of the first anniversary of the May 19, 2026 grant or the next annual stockholder meeting.

When do Asit Parikh’s newly granted Phathom (PHAT) RSUs vest?

All 24,122 RSUs vest on the earlier of the first anniversary of the May 19, 2026 grant date or the next annual meeting of stockholders, provided Parikh continues serving on Phathom’s board through that vesting date.

What happened to Asit Parikh’s Phathom stock options after the exercise?

The option giving a right to buy 17,500 Phathom shares at $4.95 was exercised and then fully disposed of back to the issuer. After this disposition, no shares remain subject to that particular option grant in the filing.